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INTRODUCTION
Cytomegalovirus (CMV) disease is a signiﬁcant compli-
cation of allogeneic progenitor cell transplantation that is
particularly frequent in CMV-seropositive patients with
CMV-seropositive donors. Even with preemptive ganci-
clovir therapy, CMV disease remains a serious problem [1].
The treatment of established CMV disease (pneumonia or
enteritis) with antiviral chemotherapy and intravenous
immunoglobulin has been only partially effective, and the
mortality rate for patients developing CMV pneumonia
remains greater than 50% [2,3]. Studies by Riddell et al. and
Walter et al. have shown that cellular immunity to CMV
can be safely restored and that the incidence of CMV dis-
ease can be significantly reduced if cellular immunity is
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ABSTRACT
Cytomegalovirus (CMV) infection is a serious complication of allogeneic bone marrow transplantation (BMT). CMV
disease can usually be prevented by passive immunization with donor-derived CMV-pp65–specific T-cell clones if pro-
vided early post-BMT. The classic method of generating CMV-specific T-cell clones requires donor-derived fibroblast
lines infected with CMV as stimulators, thus limiting the availability of CMV immunotherapy to those patients for
whom a donor skin biopsy can be obtained 6 to 8 weeks pretransplantation. To overcome this limitation we have used
monocyte-derived dendritic cells (DCs) to induce donor anti-CMV cytotoxic T lymphocytes (CTLs). Matured, adeno-
pp65–infected DCs were added at day 0 and at day 7 of a 2-week culture of donor peripheral blood mononuclear cells.
DC-primed cultures were compared with cultures stimulated in an identical fashion with CMV-infected fibroblasts or
with adeno-pp65–infected freshly isolated blood monocytes. Specific killing of CMV-infected fibroblasts was detected
in all except the culture stimulated with pp65-infected monocytes. DCs infected after maturation elicited greater CTL
activity than did DCs matured after infection. A series of 5 CD8+ clones from a fibroblast-stimulated culture and
7 CD8+ clones from a mature-DC–stimulated culture derived from a single HLA-A*0201+ individual were character-
ized. All 12 clones lysed autologous CMV-infected fibroblasts. All except 1 clone from the CMV-infected fibroblast
arm (fibroblast arm) lysed vaccinia-pp65–infected B-lymphoblastoid cell lines (BLCLs); none lysed vaccinia-
pp150–infected or noninfected BLCLs. Ten of 10 CD8+ clones tested were restricted by HLA-A*0201. Seven of the
12 clones were Vβ6+ (2 from the fibroblast arm and 5 from the DC arm) with an identical Vβ6.1-J1.4 sequence. Three
clones from the fibroblast arm and 5 clones from the DC arm recognized the pp65 peptide NLVPMVATV (amino
acids [aa], 495-503). These data show that CMV-specific T-cell clones with similar restriction patterns, T cell–receptor
usage, and specificity can be generated using monocyte-derived pp65-infected–DC or CMV-infected–fibroblast stimu-
lators. This approach should broaden the applicability of CMV-specific T-cell immunotherapy to a wider spectrum of
patients by reducing the time required to generate CMV-specific T-cell clones.
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provided early posttransplantation in the form of adoptively
transferred CMV-specific cytotoxic T–lymphocyte (CTL)
clones [4-6]. The internal matrix proteins, pp65 and pp150,
are the dominant CMV antigens recognized by clones
known to confer protective immunity [7]. Optimal protec-
tion requires the presence of both CD8+ and CD4+ CMV-
speciﬁc T-cell immunity in this setting [5,8].
CMV does not readily replicate in hematopoietic cells in
vitro, but is infectious for ﬁbroblasts. Our current methodol-
ogy requires us to obtain skin biopsies from the progenitor
cell donor at least 6 weeks prior to transplantation in order
to have established ﬁbroblast cell lines (3-4 weeks), primed
CTL responses (2 weeks), isolated clones (2 weeks), and
expanded cell lines to infusion-dose levels (2-4 weeks) by the
target 4-to-5-week posttransplantation window. Given the
sometimes-urgent nature of transplantation scheduling, this
amount of lead time may not be possible.
Several alternative approaches to generating CMV-speciﬁc
CTL lines or clones have recently been described. Epstein
Barr virus (EBV)-transformed B-lymphoblastoid cell lines
(BLCLs) transfected with a retrovirus vector to express
CMV pp65 have been used to simultaneously stimulate T-cell
responses to EBV and CMV [9,10]. Likewise, Retiere et al.
[11] have used BLCLs stably transfected via electroporation
using plasmid vectors to generate CMV IE1–specific and
CMV pp65–speciﬁc T-cell clones. Although these 2 approaches
would eliminate the need to obtain skin biopsies for the
establishment of fibroblast cell lines, a minimum of 3 or
4 weeks are still required to generate and transfect the
BLCLs before priming the bulk cultures if autologous
BLCLs are used. CTLs speciﬁc for CMV pp65 can be easily
identified in peripheral blood using HLA tetramers, and
studies in other systems have shown that antigen-specific
CTL clones suitable for immunotherapy may be derived in
as short a time period as 6 weeks by sorting for tetramer-
binding cells [12-15]. However, this approach would need to
be tailored for a given peptide and HLA allele and, thus,
would not be a system that could be used for all eligible
patients. Perhaps more useful are approaches such as that
taken by Arrode et al. [16], who have used dendritic cells
(DCs) that have acquired antigen via endocytosis of apop-
totic bodies from CMV-infected, TNF-α–treated ﬁbroblast
cell lines to stimulate anti-pp65 CTLs. In another novel
approach, Gyulai et al. [17] have induced CMV-specific
CTLs by using autologous peripheral blood mononuclear
stimulator cells producing CMV antigens following infection
with canarypox virus vectors that encoded HCMV pp65,
IE1-exon 4, gB, pp150, or pp28.
To be able to provide adoptive immunotherapy for
CMV to more patients, we have explored another alterna-
tive method to generate anti-CMV CTL clones. Here we
report our successful attempts to generate bulk-culture
CMV-specific CTL activity from 2 CMV-seropositive
donors using autologous monocyte-derived DCs infected
with an adenovirus vector encoding the immunodominant
CMV antigen, pp65. A series of CMV-speciﬁc clones were
established from the CMV-infected–fibroblast–stimulated
bulk culture and from the pp65-infected–DC–stimulated
bulk culture from 1 of the donors and are characterized here




Peripheral blood mononuclear cells (PBMCs) and skin
biopsies were obtained from 2 CMV+ healthy laboratory
donors (donors 1 and 2). Informed consent was obtained
from all donors before samples were collected.
Construction of the Adeno-pp65 Vector
The open reading frame (ORF) of HCMV UL83 (pp65)
was recovered by polymerase chain reaction (PCR) from
plasmid pp65RSV containing the gene inserted in a murine
retrovirus (originally from B. Plachter, Mainz, Germany).
The PCR product was ligated into the SK plasmid (Strata-
gene, La Jolla, CA), and its sequence was confirmed. The
pMV60 and pJM17 plasmids of Wilkinson and Akrigg were
used to recombine the pp65 ORF into an E1a-defective ade-
novirus5 construct and recombinant virus isolated in com-
plementing 293 cells [18]. The pp65 expression is under the
regulation of HCMV MIE enhancer/promoter in this vec-
tor. Virus pools prepared in 293 cells had titers of approxi-
mately 1010 pfu/mL when titered on 293 cells.
Vaccinia-pp65 and -pp150 Vectors
Recombinant vaccinia viruses encoding pp65 and pp150
were prepared as stocks in the 143B cell line. The cells were
infected at a multiplicity of infection (MOI) of 10, cultured
for 48 hours, and lysed by 3 freeze/thaw cycles to release
virus particles. The supernatant was clariﬁed by centrifuga-
tion and stored in aliquots at –80°C. Titers ranged from 107
to 108 pfu/mL.
Monocyte-Conditioned Medium
Immunoglobulin-coated 100-mm tissue culture dishes
(Corning Glass Works, Corning, NY) were prepared by
adding 2 mL human γ-globulin (Polygam, Baxter Healthcare
Corp, Glendale, CA), at 10 mg/mL in phosphate-buffered
saline solution (PBS), for 3 to 5 minutes. The γ-globulin was
removed and saved for reuse (4-6 times). The plates were
rinsed 3 times with 5 mL PBS at room temperature. No
more than 5 mL or 50 × 106 PBMCs were added to each
coated plate and incubated for 2 hours at 37°C. The nonad-
herent cells were removed and discarded. Fresh medium
containing 1% autologous plasma or pooled human AB
serum (C-Six Diagnostics, Mequon, WI) was added and
incubation was continued for 24 hours at 37°C. The medium
was then centrifuged to remove cells and stored frozen until
used for DC maturation.
DC Generation and Maturation
DC preparation was based on the method described by
Bender et al. [19]. Briefly, 106 PBMCs in 1 mL of RPMI
containing 1% autologous heparinized plasma were incu-
bated at 37°C for 2 hours in 6-well plates. The nonadherent
cells were removed and 3 mL of medium containing 10%
autologous plasma, 1500 U/mL granulocyte-macrophage
colony–stimulating factor (GM-CSF) (Leukine [sar-
gramostim]; Immunex, Seattle, WA) and 1200 U/mL inter-
leukin (IL)-4 (Genzyme Corp, Framingham, MA) was
added. On days 2, 4, and 6 of culture, 0.3 mL of medium
was removed and replaced with 0.5 mL medium with
1000 U/mL GM-CSF and 800 U/mL IL-4. At the time of
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the day 4 feeding, the cultures were transferred to fresh wells
to further deplete the cultures of adherent mononcytes. On
day 7, the immature (nonadherent) DCs were collected from
the plate by aspiration, then pelleted and suspended in 2 mL
of the original medium plus 1 mL monocyte-conditioned
medium (MCM); the suspension was then added to the plate
wells. The cells were left to mature for 2 additional days, at
which time the nonadherent, mature DCs were removed
from the wells and prepared for use.
Infection of Dendritic Cells or Monocytes With
Adeno-pp65
DCs were infected with adeno-pp65 either after 7 days
of culture with GM-CSF and IL-4 (immature DCs) or at
day 9 after maturation with MCM. On the day of infection,
the nonadherent DCs were pooled and pelleted by centri-
fugation. Approximately 2 × 106 DCs were suspended in
X VIVO 15 (BioWhittaker, Walkersville, MD) + 1% human
serum albumin (HSA) (Albumar; Baxter Healthcare Corp,
Deerfield, IL), pelletted a second time, then suspended in
0.5 mL of X-VIVO 15. After transfer of the DC suspension
into a sterile microfuge tube, 0.5 mL of adeno-pp65
adjusted to an MOI of 250 to 500 was added, and the cells
were incubated for 2 hours at 37°C. The cells were washed
twice with X-VIVO 15 + 1% HSA and either suspended for
culture with responders or exposed to 2 additional days of
MCM prior to culture with PBMC responders. A responder-
to-DC ratio of 100:1 was used. Freshly isolated monocytes
were infected in an identical manner.
CMV Infection of Fibroblasts
Fibroblasts autologous to the CMV-effector PBMCs
were split and adjusted to 105 cells/mL in RPMI containing
20% fetal bovine serum (FBS); 2.5 mL of this mixture was
added to 2-3 wells of a 6-well plate. The cells were incu-
bated overnight at 37°C and 5% CO2 to allow ﬁbroblasts to
attach. After incubation, the medium was removed and the
monolayers washed once with 5 mL per well of PBS without
Ca2+ or Mg2+. CMV-containing supernatant (AD169) was
added to achieve an MOI of 5 (volume based on the super-
natant titer). The total culture volume was adjusted to 1 mL
per well and the plates incubated for 4 hours at 37°C and
5% CO2. The virus-containing supernatant was removed
and the monolayers washed with 5 mL per well of PBS, a
total of 3 times prior to addition to effectors.
Priming of CMV-CTL Effectors
Four stimulator-cell variations were used to generate
CMV effectors: (1) ﬁbroblast arm: CMV-infected ﬁbroblasts;
(2) mature-DC arm: DCs infected with adeno-pp65 after
7 days culture with GM-CSF and IL-4 and 2 days with
MCM; (3) immature-DC arm: DCs infected with adeno-
pp65 after 7 days culture with GM-CSF and IL-4, then
matured after infection for 2 days with MCM; and (4) mono-
cyte arm: freshly adherent adeno-pp65–infected monocytes.
In all combinations, PBMCs from the autologous CMV-
seropositive donor were adjusted to 106/mL in RPMI con-
taining 20% pooled human serum, penicillin/streptomycin,
L-glutamine, and 25 µmol/L β-mercaptoethanol (Sigma,
St. Louis, MO) and then added to wells containing the
appropriate stimulator cells. The cultures were incubated at
37°C and 5% CO2 for 7 days, at which time the effectors were
pelleted and suspended in fresh medium at 2 × 106 cells/mL.
Cryopreserved autologous PBMCs were thawed, adjusted to
2 × 106 cells/mL, irradiated to 1500 cGy, and added in equal
volumes to serve as feeders. The primed-PBMC/feeder mix-
ture (106 primed PBMCs/mL) was added to freshly pre-
pared stimulator cells of the appropriate arm. The cultures
were fed 48 and 96 hours after each restimulation by remov-
ing the top 2.5 mL of culture medium and adding 2.5 mL
fresh medium with 200 IU/mL IL-2 (Chiron, Emeryville,
CA) per well. Incubation was continued for 7 additional
days prior to testing and cloning.
Bulk-Culture 51Cr-Release Assay and Target
Preparation
Bulk cultures were tested for cytolytic reactivity to 51Cr-
labeled targets. The targets included CMV-infected fibro-
blasts, vaccinia-pp65–infected autologous or allogeneic
BLCLs, vaccinia-pp150–infected autologous or allogeneic
BLCLs, and noninfected ﬁbroblasts and BLCLs.
Fibroblasts were split 3 days prior to assay and were
incubated for 48 hours in 100 U/mL interferon (IFN)γ to
up-regulate HLA class I expression. The IFNγ-treated
ﬁbroblasts were incubated overnight with 200 µCi of 51Cr
(Na2-
51CrO4; ICN Pharmaceuticals, Costa Mesta, CA), with
and without CMV (MOI of 5). The cells were trypsinized
and washed prior to plating as targets (5000 cells/well) in
the 51Cr-release assay.
BLCLs were infected with recombinant vaccinia vector
expressing pp65 or pp150 to avoid detection of potential ade-
novirus-specific effectors. BLCLs were infected with the
recombinant vaccinia (MOI of 10) together with 200 µCi of
51Cr in 0.5 to 1.0 mL of medium for 2 hours at 37°C. At the
end of 2 hours, the cells were diluted 10-fold with RPMI con-
taining 10% FBS and incubated for an additional 14 to 18 hours
before washing and plating as targets (5000 cells/well) in the
51Cr-release assay.
The 51Cr-release assay was performed at 3 or more
effector-to-target ratios (E:Ts) ranging from 25:1 to 3:1.
Assays using clones included 100 IU/mL recombinant (r)IL-
2 in the medium (RPMI with 10% FBS). After 5 hours at
37°C, supernatants were collected on ﬁber ﬁlters (Molecular
Devices Corp, Sunnyvale, CA) and radioactivity was meas-
ured in a gamma counter. Spontaneous release was meas-
ured using medium with targets (no effectors) and maximum
release was measured using 0.5% Triton X-100 with targets.
Speciﬁc lysis was calculated as:
[(cpm test – cpm spontaneous) ÷ (cpm maximum – 
cpm spontaneous)] × 100.
Cloning and Expansion of CMV CTLs
Bulk cultures were depleted of CD4+ cells using
immunomagnetic bead separation (Dynabeads M-450, CD4-
Coated Immunomagnetic Beads; Dynal Biotech Inc, Lake
Success, NY). Cells were then plated at 0.3 or 1.0 cell per well
in replicate 96-well plates containing autologous-irradiated
PBMCs (5 × 104 cells/well), autologous-irradiated BLCLs
(104 cells/well), and CMV-infected fibroblasts (1.5 × 103
cells/well). The plates were incubated 10 to 12 days in a well-
humidiﬁed atmosphere of 5% CO2 at 37°C. Growing wells
were screened by removing one third of the culture volume
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into each of 2 new plates containing 51Cr-labeled CMV-
infected and CMV-noninfected autologous fibroblasts.
Clones that lysed infected but not uninfected ﬁbroblasts were
selected for rapid expansion and further characterization.
Rapid expansion was performed using OKT3 in medium
containing PBMC feeders (PBMC to T cell–clone ratio,
500:1) and BLCL feeders (BLCL to T cell–clone ratio, 100:1)
and rIL-2 as previously described by Riddell et al. [20].
Spectratyping/Sequencing Methods
Spectratyping was performed using a modification of
the method described by Gorski et al. [21]. This method
evaluates the T-cell repertoire of a lymphocyte sample using
reverse transcriptase–PCR with 24 different Vβ primers and
1 constant β primer to amplify the β chain of the comple-
mentarity-determining region (CDR)3 of the T-cell recep-
tor. The PCR products were separated by gel electrophoresis
to identify the Vβ family(ies) used by the sample in ques-
tion. Using this methodology, each “clone” is identiﬁed by
the TCR β expressed.
Direct DNA sequence analysis of the complementary
(c)DNA from the clones was performed using the Taq Dye
Deoxy-Terminator Cycle Sequencing Kit (Applied Biosys-
tems, Foster City, CA). The sequence reaction was analyzed
by ABI 373 Sequencing Software (Applied Biosystems).
Peptide Specificity Analysis
The pp65 peptide (aa, 495-503) (pp65495-503) was synthe-
sized and puriﬁed (New England Peptide, Fitchburg, MA).
The ability of the clones to recognize this known HLA-
A*0201–restricted peptide [22] was tested in a modified
CTL assay using T2 cells (174 × CEM.T2 hybrid, CRL-
1992), TAP-deﬁcient HLA-A*0201+ BLCLs maintained in
RPMI medium [Life Technologies, Rockville, MD] with
10% FCS [23]. Briefly, T2 cells were incubated overnight
with 100 µCi/mL 51Cr, washed, and then 100 µL of this mixture
containing 103 labeled cells was pulsed with varying amounts
of puriﬁed peptide for 1 hour. Effector cells were then added
at 104 cells/well (E:T of 10:1) in a volume of 100 µL (total
reaction volume, 200 µL). The amount of 51Cr released after
4 hours was determined by liquid scintillation counting.
Spontaneous release was measured using medium with targets
(no effectors) and maximum release was measured using
0.2% Triton X-100 with targets. Speciﬁc lysis was calculated as:
[(cpm test – cpm spontaneous) ÷ (cpm maximum – 
cpm spontaneous)] × 100.
RESULTS
Effect of DC Maturation Stage at the Time of 
Adeno-pp65 Infection on the Generation of 
CMV-Specific CTLs
Immature DCs are known to be superior at taking up
antigen from the environment, whereas mature DCs are
superior at presenting antigen to the immune system [24].
The DC maturation stage for optimal infection with adeno-
pp65 is not described. Therefore, we compared the ability
of DCs infected with adeno-pp65 before or after maturation
to stimulate CMV-specific CTLs. Because maturation is
required to maintain a stable DC phenotype, we allowed
DCs infected at an immature stage to differentiate to matu-
rity before exposing them to the PBMC responders. In the
initial experiment, monocyte-derived DCs from donor 1
were infected with adeno-pp65 after 7 days of culture with
GM-CSF + IL-4; the DCs were then allowed to mature an
additional 2 days in MCM before adding them to donor
PBMCs (immature-DC arm). In the same experiment we
infected a separate aliquot of DCs after 2 days of maturation
in MCM (mature-DC arm), along with a control arm of
effectors stimulated in the traditional way using CMV-
infected ﬁbroblasts (ﬁbroblast arm). DC maturity in our cul-
ture system was determined by the increase in expression of
the CD83 antigen on bright HLA-DR+ CD14– cells [19].
All of the effectors were tested after 2 weeks of culture (with
1 restimulation using the same conditions as the ﬁrst stimu-
lation) in the same 51Cr-release assay. The results (panel A
of Figure 1) show high lytic activity in the mature-DC arm
(39%, E:T of 25:1), although this lytic activity was not as
high as that in the ﬁbroblast arm (78%, E:T of 25:1). How-
ever, the immature-DC arm generated relatively low lytic
activity (13%, E:T of 25:1). There was no lysis of uninfected
ﬁbroblasts by effectors from any of the arms. Therefore, all
further experiments were performed using DCs infected
with adeno-pp65 after maturation.
Figure 1. Effect of dendritic cell (DC) maturity at the time of adeno-
pp65 infection on generation of cytomegalovirus (CMV)-specific
cytolytic T–lymphocyte (CTL) activity. A, Data from donor 1. B, Data
from donor 2. Autologous DCs were infected with adeno-pp65 either
after 7 days of culture with granulocyte-macrophage colony–stimulat-
ing factor (GM-CSF) and interleukin (IL)-4 (immature DCs, ) then
matured an additional 2 days prior to culture with peripheral blood
mononuclear cell (PBMC) responders (A), or were infected at day 9
after maturation with monocyte-conditioned medium (MCM) ()
prior to culture with PBMCs (A and B). The effectors generated from
the DC cultures were compared with CTLs generated by coculture
with CMV-infected autologous fibroblasts (, A and B) and with
adeno-pp65–infected monocytes (, B). The results from 2 experi-
ments are shown as specific lysis of CMV-infected autologous fibro-
blasts (closed symbols) or mock-infected ﬁbroblasts (open symbols) in a
5-hour 51Cr release assay at the indicated effector-to-target ratios. 
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A second experiment, using donor 2, was performed to
ensure that the adeno-pp65–infected autologous DCs could
stimulate CMV-specific CTLs from more than 1 donor.
In this experiment, an experimental arm using adeno-
pp65–infected freshly isolated monocytes was included
together with the fibroblast arm and mature-DC arm. As
shown in panel B of Figure 1, the mature-DC arm again
generated high lytic activity (28%, E:T of 12.5:1) to CMV-
infected fibroblasts, although not as high as the fibroblast
arm (39%, E:T of 12.5:1), and as expected the monocyte
arm gave very low lytic activity (5%, E:T of 12.5:1). Unin-
fected targets were not lysed.
Specificity of CMV-Specific CTLs
Both the pp65 and the pp150 antigen have previously
been shown to be immunodominant CMV antigens.
Because the CTL response in the DC cultures was stimu-
lated against only pp65, we wanted to conﬁrm that this anti-
gen was indeed recognized by the CTLs. Shown in Figure 2
are the results from donor 2, conﬁrming that pp65 is a tar-
get of CTLs from both the mature-DC and the ﬁbroblast
arms, and that pp150 is weakly recognized only by the
CTLs from the ﬁbroblast arm. Similar results were obtained
for subsequent CTLs generated from donor 1 using the
ﬁbroblast and the mature-DC arms (not shown).
CMV-Specific CTL Cloning
Cells from the fibroblast-arm and from the mature-
DC–arm bulk cultures from donor 1 were depleted of CD4+
cells and then cloned. For the cloning step, CMV-infected
ﬁbroblasts were used as the antigen stimulus and the clones
were screened based on recognition of CMV-infected ﬁbro-
blasts. A total of 7 clones from the ﬁbroblast arm and 9 clones
from the mature-DC arm were expanded to sufﬁcient num-
bers for further characterization.
Phenotype analysis revealed that 2 clones each from the
ﬁbroblast and the mature-DC arms were CD4+ T cells and
the rest were CD8+ T cells. The 4 CD4+ clones showed the
highest lytic activity to CMV-infected fibroblast targets.
Each of the clones was further tested for recognition of pp65
and all except 1 clone was tested for reactivity to pp150.
None of the tested clones recognized vaccina-pp150, and all
except the 4 CD4+ clones and 1 CD8+ clone (R17G12) from
the ﬁbroblast arm strongly lysed vaccina-pp65.
Ten of the 11 pp65-speciﬁc CD8+ clones were tested to
determine their HLA restriction patterns. BLCLs that were
matched for only 1 of the Class IA and B locus alleles of the
donor were selected, infected with vaccina-pp65, and tested
in a 5-hour 51Cr-release assay. As shown in Figure 3, each of
the clones strongly lysed only the autologous BLCLs and
BLCLs sharing the donor’s HLA-A*0201 allele. These
included 4 clones from the ﬁbroblast arm as well as 7 clones
from the mature-DC arm. The uninfected BLCLs were not
lysed (data not shown). The full HLA typing of the BLCLs
used in this experiment is shown in Table 1.
T Cell–Receptor Usage
All of the clones were characterized by TCR-Vβ spectra-
typing to conﬁrm clonality and to determine the predominant
Figure 2. Speciﬁcity of ﬁbroblast- and dendritic cell (DC)-generated
cytomegalovirus (CMV)-speciﬁc cytolytic T lymphocytes (CTLs); all
data are from donor 2. Bulk culture effectors from the ﬁbroblast-stimu-
lated arm (), the mature-DC arm (), and the monocyte arm ()
were tested against autologous vaccinia-pp65–infected (closed symbols)
and vaccinia-pp150–infected (open symbols) BLCLs in a 5-hour 51Cr
release assay at the indicated effector-to-target ratios. Mock-infected
targets were negative in all cases (not shown). 
Figure 3. HLA-restriction pattern of clones generated from dendritic
cell (DC)- and fibroblast-stimulated cytomegalovirus (CMV)-specific
cytolytic T–lymphocyte (CTL) cultures. Clones generated from both the
ﬁbroblast-stimulated arm (F) and from the mature-DC–stimulated arm
(D) were tested against the autologous vaccinia-pp65–infected B-lym-
phocyte cell lines (BLCLs) and against BLCLs selected to share only a
single Class I HLA-A– or HLA-B–locus allele with the donor (donor 1)
designated as follows: autologous BLCLs ( ), A*0201 ( ), A*1101 ( ),
B*2705 ( ), and *B4402 ( ). Full-HLA typing of the BLCLs is shown
in Table 1. Data are shown as the % speciﬁc lysis at an effector-to-target
ratio of 12.5:1 in a 5-hour 51Cr release assay. In all experiments, unin-
fected BLCLs from the same donors were not lysed (not shown).
C.A. Keever-Taylor et al. 
252
Vβ family in use. The sequence across the Vβ-J region was
determined from cDNA extracted from the clones. The
results summarized in Table 2 unexpectedly showed that
2 of the functional clones (clones D13C2 and D16F3) in fact
represented 2 different Vβ families. Each of 2 subclones
obtained from D13C2 expressed only Vβ5.3, whereas 6 sub-
clones from D16F3 expressed only Vβ6, indicating that
there were in fact 2 separate populations in both cultures
and not a dual expression of TCR.
Two CD8+ clones from the fibroblast arm and 2 from
the mature-DC arm expressed Vβ13, whereas the single
CD8+ clone from the ﬁbroblast arm that failed to recognize
pp65 expressed Vβ2. One clone each from the mature-DC
arm expressed Vβ5.3 or Vβ22. The most frequent variable
gene segment expressed was Vβ6, present on 7 of the 12 CD8+
clones, including the 2 functional clones with more than
1 population. In all cases, the Vβ6 variable gene segment
represented an identical Vβ6.2-J1.4 sequence (CASSLAP-
GATNEKLFFG). This overrepresentation of Vβ6 included
2 clones from the fibroblast arm and 5 clones from the
mature-DC arm.
To determine the reason for the large number of Vβ6.2+
clones, we compared the spectratype of 4 of the clones with
that of the bulk cultures and starting PBMCs as shown in
Figure 4. There was a predominant Vβ6 band in the starting
PBMCs; however, this CDR3 band was 1 amino acid longer
than the predominant Vβ6 band shared by both bulk cul-
tures and each of the 4 clones. This ﬁnding suggests that for
Table 1. Full HLA Typing of B-Lymphocyte Cell Lines (BLCLs) Used to Determine HLA Restriction
BLCL ID A B C DRB1 DRB3 DRB4 DRB5 DQ
Autologous 0201 2705 0202 0701 01 0201/2
1101 4402 0501 1601 02 0502
A0201 0201 0702 0702 1301 0101 0603
0301 5101 1402 0404 0103 0302
A1101 3301 3501 0401 1401 0202 0501
1101 1402 0802 0102 0202 0503
B2705 0301 2705 0102 0101 0501
0301 2705 0102 0101 0501
B4402 0301 4402 0501 1201 0202 0301
2402 5201 1202 1502 0102 0601
Table 2. Summary of Clonal Phenotypes, T Cell–Receptor (TCR) Usage, and Speciﬁcity*
CMV+ HLA
Clone Phenotype Fibroblast pp65 pp150 Restriction TCR (Vβ/J) TCR Vβ/J Sequence
D3B1 CD4 51 4 0 ND Vβ14-J2.1 CASSSPRGSGGPARNEQFFG
D22D4 CD4 72 5 0 ND Vβ14-J2.1 CASSSPRGSGGPARNEQFFG
D21D9 CD8 15 56 0 A0201 Vβ6.2-J1.4 CASSLAPGATNEKLFFG
D20A5 CD8 33 68 0 A0201 Vβ6.2-J1.4 CASSLAPGATNEKLFFG
D18H7 CD8 23 66 0 A0201 Vβ6.2-J1.4 CASSLAPGATNEKLFFG
D16F3 CD8 17 50 0 A0201 Vβ6.2-J1.4 CASSLAPGATNEKLFFG
Vβ13-J1.1 CASSYFGYQAEAFFG
D13C2 CD8 17 58 0 A0201 Vβ6.2-J1.4 CASSLAPGATNEKLFFG
Vβ5.3-J1.2 CASSLEGDEDPHGYTFG
D10G8 CD8 14 55 0 A0201 Vβ22-J2.1 CASSGSSGGFYNEQFFG
D2A5 CD8 20 53 0 A0201 Vβ13-J1.1 CASSYFGYQAEAFFG
F8C2 CD4 31 0 ND ND Vβ24-J2.6 CATSRDPTGVTGANVLTFG
F12D6 CD4 74 13 0 ND Vβ24-J2.6 CATSRDPTGVTGANVLTFG
F21E12 CD8 14 58 0 A0201 Vβ6.2-J1.4 CASSLAPGATNEKLFFG
F9A8 CD8 19 64 1 A0201 Vβ13-J1.1 CASSYFGYQAEAFFG
F17G12 CD8 15 0 0 ND Vβ2-J1.4 CSARDMTGEVGNEKLFFG
F7C12 CD8 23 53 0 A0201 Vβ13-J1.1 CASSYFGYQAEAFFG
F15F4 CD8 15 78 5 ND Vβ6.2-J1.4 CASSLAPGATNEKLFFG
*A summary of the screening data on clones generated from the ﬁbroblast-stimulated cultures (designated as F for “Fibroblast arm”) and from
the DC-stimulated cultures (designated as D) obtained from donor 1. Clones were tested for cell surface phenotype, % speciﬁc lysis at an effector-to
target ratio of 12.5:1 of autologous cytomegalovirus (CMV)-infected ﬁbroblasts, vaccinia-pp65– and vaccinia pp-150–infected autologous B-lym-
phocyte cell lines, HLA-restriction pattern (see Figure 3), TCR–Vβ-J sequence, and CMV-peptide speciﬁcity. Each of the clones that were tested
for HLA-restriction with the exception of clones D13C2 and D16F3 were found to be restricted by the same pp65403-505 peptide, NLVPMVATV.
Clones D13C2 and D16F3 were conﬁrmed by subcloning to consist of 2 distinct clones. ND indicates not determined.
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donor 1, T cells with the TCR Vβ6.2-J1.4 represent a mem-
ory CMV–reactive clone that was highly expanded only
after re-exposure to virus-infected fibroblasts or to CMV
pp65 during the in vitro culture.
Peptide Specificity
We wanted to determine the peptide speciﬁcity of the
clones to assess whether there were differences in the ﬁne
speciﬁcity between clones generated from the ﬁbroblast arm
versus the mature-DC arm. We ﬁrst synthesized and puri-
ﬁed the well-characterized pp65495-503 epitope known to be
restricted by HLA-A*0201. T2 cells were loaded with vary-
ing amounts of peptide and tested in a 4-hour 51Cr-release
assay. There was strong lysis of this peptide even at low con-
centrations by each of the clones that were tested, as shown
in Figure 5, even though not all of the clones shared the
same TCR sequence. Thus, there was no difference in the
ﬁne speciﬁcity between clones generated after priming with
CMV-infected ﬁbroblasts versus those generated after prim-
ing with adeno-pp65 infected DCs.
DISCUSSION
Analysis of endogenous immune reconstitution in
human BMT recipients demonstrates the protective role of
CD8+ cytotoxic T-cell responses against CMV disease and
specifically shows that BMT patients respond predomi-
nantly to the known immunodominant viral antigens [7].
Among the most predominant viral antigens recognized by
CMV-speciﬁc CTLs is the lower-matrix 65-kd phosphopro-
tein (pp65), 1 of the most abundant structural proteins of
the virion [22]. The majority of healthy CMV-seropositive
donors have a very high precursor frequency to pp65 that
includes both CD4+ and CD8+ T cells [12,17,25,26]. Indeed,
even in individuals coinfected with multiple viruses, the
response to CMV pp65 can be found to dominate [27]. Up
to 85% of healthy donors have CTLs recognizing pp65 from
natural infections [28]. The immunodominance of pp65 in
lytic infection compared to that of IE1 may be explained by
its inhibition of proteasomal processing of IE1 through an
associated kinase activity [29], thus preventing IE1 from
being presented to the immune system. HLA-restricted T-cell
responses to at least 10 different pp65-derived peptides have
been described [30]. Therefore, we felt that a gene-based
rather than a peptide-based approach to stimulating the T-cell
response to pp65 in our progenitor-cell donors offered sev-
eral advantages. The chief advantage is the ability to prime
responses to any of the multiple epitopes of pp65 without
the need to generate specialized peptides based on the HLA
type of the donor. A second advantage is that CTLs raised
to peptide-pulsed antigen-presenting cells (APCs) may not
be lytic to endogenously derived antigen as has commonly
been seen in the inﬂuenza system [31]. Although CMV pep-
tides such as pp65495-503 do stimulate responses to endogenous
antigen [32], this may not be the case for all CMV-derived
peptides. A third advantage is the potential to circumvent
the need for autologous fibroblast cell lines by delivering
pp65 into an APC that is more readily obtained, such as
monocyte-derived DCs.
Dendritic cells are potent professional APCs that
express both HLA class I and II molecules together with
costimulatory molecules that mediate the physical interac-
tion and signal transduction required for T cells to respond
to antigenic stimuli. Blood monocytes can be readily differ-
entiated into fully functional DCs within 6 to 7 days using a
cytokine combination of GM-CSF and IL-4. The DCs gen-
erated in this fashion display an unstable, immature pheno-
type unless induced to differentiate further into mature DCs
by additional signals, including those found in an MCM
[24]. To present the entire pp65 protein, we used a virally
mediated gene-transfer approach using an adenovirus vector
previously shown to be a highly efﬁcient and reproducible
method of gene transfer into DCs [33]. We optimized the
conditions required for presentation of pp65 to donor T cells
in bulk culture experiments and characterized the respond-
ing T cells for specificity at both the protein and peptide
levels, for HLA restriction, and for T cell–receptor usage.
These ﬁndings were compared with those of T cells gener-
ated using CMV-infected ﬁbroblasts as stimulators.
Immature DCs are superior to mature DCs in antigen
uptake, whereas mature DCs are optimal antigen presenters
[24]. Therefore, we ﬁrst determined the optimal timing for
DC infection with adeno-pp65. Immature DCs were
infected then matured by an additional 2 days in MCM
before coculturing them with responder T cells. The result-
ing CTL response was compared with that generated by
DCs that were infected with adeno-pp65 infection after
maturation. Superior CTL activity against CMV-infected
fibroblasts was generated when the adeno-pp65 infection
was performed after DC maturation as shown in Figure 1.
We further conﬁrmed that fresh monocytes were not sufﬁ-
cient as APCs when infected with adeno-pp65. Although
substantial CTL reactivity to CMV-infected ﬁbroblasts was
generated in the DC-primed cultures, both donors showed
higher lytic activity when CMV-infected fibroblasts were
used to prime the CTL responses. This higher lytic activity
was likely due to the priming of CTLs to CMV antigens in
addition to pp65 (Figure 2).
Figure 4. TCR-Vβ6 spectratypes; all data are from donor 1. Spec-
tratype data from the TCR-Vβ6 family are shown for fresh donor
peripheral blood mononuclear cells (PBMCs), lane 1; mature–den-
dritic cell (DC)-primed cytolytic T–lymphocyte (CTL) bulk culture,
lane 2; cytomegalovirus (CMV)-infected ﬁbroblast-primed CTL bulk
culture, lane 3; and 4 T-cell clones derived from the mature-
DC–primed bulk culture including clones D21D9, lane 4; D16F3, lane
5; D13C2, lane 6; and D18H7, lane 7. The predominant complemen-
tarity-determining region (CDR)3 in the 2 bulk cultures is 1 amino
acid shorter than the predominant Vβ6 CDR3 in the donor PBMCs.
Each of the 4 clones share the CDR3 predominant in the bulk culture
from which they were derived. 
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Having established that we could generate CMV-speciﬁc
CTLs from adeno-pp65–infected mature DCs, we went on
to generate and characterize clones derived from DC-stimu-
lated and ﬁbroblast-stimulated bulk cultures from 1 of the
2 healthy donors. Here we found that all of the CD8+
clones, regardless of the manner in which they were initially
primed, recognized pp65 and were restricted by HLA-
A*0201. This finding was not surprising given that the
response to pp65 is particularly strong for HLA-A2+ donors
[28]. The peptide that was recognized, NLVPMVATV
(pp65495-503), represents 1 of 3 known HLA-A*0201 restricted
peptides in the pp65 antigen that can generate a CTL
response [26]. It has been previously reported that the
response to pp65 in certain HLA-A2+ individuals is highly
focused and may be restricted to a limited number of TCRs
[22,32,34,35]. This focused response was seen at the bulk
culture level by the highly restricted repertoire revealed by
spectratype (data not shown). Of particular note is the fact
that pp65495-503-specific clones with different TCRs were
expanded using both CMV-infected ﬁbroblasts and adeno-
pp65–infected DCs as the antigen stimulus, indicating that
it was not the isolated presentation of pp65 that resulted in
this response. Vβ6.2-J1.4 was the most frequent TCR
expressed by the clones in our study. Although the fresh
PBMCs from donor 1 showed a predominant Vβ6 band,
this band was not the same size as that found in both the
fibroblast-primed and DC-primed bulk cultures or in the
Vβ6.2-J1.4 clones derived from those cultures. This differ-
ence in size indicates that both forms of in vitro priming
selectively expanded the same Vβ6 CMV-speciﬁc precursor
despite the fact that other Vβ6-bearing precursors predomi-
nated in the unstimulated PBMCs. Although Vβ6.2-J1.4 was
the most frequently expressed TCR, 2 other TCRs were
detected on the HLA-A2–restricted clones reactive to CMV
pp65495-503. These findings support those of Weekes et al.
[35], who have similarly observed individual donors with
multiple TCRs recognizing the identical peptide in both the
CMV and HIV system.
Our study supports the conclusion that adeno-pp65
infection of mature DCs can be used to generate CMV-
reactive CTLs that are of a similar phenotype, activity, and
specificity as clones generated using the more conventional
Figure 5. Reactivity to pp65 peptide (amino acids, 495-503) (pp65495-503). All clones were tested in a 4-hour 
51Cr-release assay to the
cytomegalovirus pp65495-503 peptide, NLVPMVATV, at an effector-to-target ratio of 10:1 with the exception of clone D18H7, which was tested at
5:1. Peptide was added to T2 targets at the indicated concentration.
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approach of virally infected–fibroblast stimulator cells.
Additional studies have further indicated that CMV-specific
T-cell clones can be generated using adeno-pp65–infected
mature DCs in the cloning plates (data not shown), thus
eliminating the need for fibroblast cell lines entirely. This
approach will reduce the time required to generate CMV-
specific T-cell clones by 2 or more weeks and will allow us
to generate clones from patients for whom donor fibro-
blast lines cannot be generated or expanded to sufficient
numbers for cloning to proceed. Clinical trials to confirm
that clones produced by this method will provide in vivo
immunity to CMV are pending. It is hoped that these
improvements will increase the number of patients who
can receive T-cell clones for CMV prophylaxis by reducing
the amount of time required to prepare the clones and by
allowing the entire procedure to be performed using only
peripheral blood donations from potential progenitor cell
donors. A combination of adenoviral vectors expressing
pp150 and the immediate early antigen, IE1, might be
used to broaden the population of responding T cells
because the CMV proteins are recognized by T cells from
different donors to varying degrees and in the context of
different MHC Class I alleles.
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